CD19 and neoplasm: Therefore, even if recent clinical studies have reported minimal GVHD incidence in recipients of allogeneic CD19 CAR.28z T cells for the treatment of B-cell malignancies (38), it cannot be excluded a different outcome when changing the treatment schedule, tumor type and CAR construct.